Haier Biomedical embarks on a leap in globalization, with overseas revenue share reaching a new high in 2025

On March 27, Haier Biomedical released its 2025 annual report. The annual report shows that in 2025, the company’s overseas revenue increased by 17.9% year over year, accounting for 36% of its main operating revenue, reaching a record high. Against the backdrop of a complex and ever-changing global trade environment, the company achieved double-digit growth across major regions including Europe, Asia-Pacific, the Americas, and Africa.

This achievement is the result of Haier Biomedical’s clear overseas expansion roadmap over the past decade and its systematically built core capabilities. From “getting out” to “moving in” and “moving up,” Haier Biomedical has gradually built four core capabilities in the global market: technological product strength, localized operational capability, synergy across new industries, and brand influence.

As far as is known, Haier Biomedical’s Eco-Drive ultra-green technology developed independently can improve energy efficiency by 30% compared with the industry’s highest level. The super-energy series ultra-low-temperature storage and preservation equipment, equipped with this technology, ranks among the top eight on the U.S. UL “Energy Star” certification list. The company became the only enterprise in China that simultaneously obtained EU MDR and the global ACT certifications. With solid product strength, the company’s ultra-low-temperature and constant-temperature product lines have secured the number one market share position in six countries, including the UK, Italy, and Australia. In terms of breakthroughs in underlying technology, the company’s independently developed 100,000 rpm ultra-high-speed centrifugation equipment improves stability by 30% versus comparable products, becoming the first domestic company to break through the technical bottleneck of ultra-high-speed centrifugation.

Under the “one country, one policy” strategy, Haier Biomedical has set up subsidiaries in four countries, including the UK and the Netherlands. It has completed localized deployments in 18 countries, including Germany, Italy, Singapore, and the UAE. The proportion of localized operation teams within overseas teams exceeds 40%. This deeply localized operating system significantly improves service response speed and delivery quality— in Italy, the company customized a U-Blood intelligent blood management system for Ferrara Hospital, exporting China’s smart blood utilization solutions to leading European hospitals; in the UK, the company provided a customized laboratory service plan for Queen Mary University within 24 hours, successfully accommodating 64 biosafety cabinets. Currently, the company has cumulatively obtained more than 400 overseas product certifications, its distribution network covers more than 800 entities, its products are sold to more than 160 countries and regions, and it serves top research institutions such as the University of Oxford, Stanford University, and the British Biological Sample Library.

In 2025, the proportion of new-industry revenue represented by smart medication, blood technology, and laboratory solutions reached 48.5%, becoming the core force driving growth. Among them, the smart medication industry grew by 18.8%, leading in export volume among domestic brands and helping China’s original AI smart pharmacy expand in multiple regions such as Southeast Asia and the Middle East. The blood technology industry grew by 14.8%; its complete plasma collection solution obtained EU MDR certification, becoming the first domestic holder of an MDR certification for plasma separation equipment, opening a new channel for exporting blood technology products.

With stable and reliable product quality, fast delivery capability, and localized response services, Haier Biomedical has maintained long-term and ongoing cooperation with nearly 80 international organizations including WHO and UNICEF, building a strong reputation and credibility in overseas markets. From the initial export of products to today’s standardized export of products and solutions, Haier Biomedical is gradually achieving a strategic upgrade from “exporting products/solutions” to “exporting brands.”

Looking to the future, Haier Biomedical has clearly proposed three-year strategic goals: accelerating global deep layout through localization, accelerating industry strategic leapfrogging through platform extensions, and using AI+ to define the future and lead the business. As technological product strength continues to be strengthened, localized deployments advance deeper, the synergistic effects across new industries accelerate and are released, and brand influence continues to accumulate, Haier Biomedical is stepping up its pace toward becoming an integrated life-science tools and intelligent manufacturing productivity platform that leads the world.

Huge volumes of information and precise analysis—All on the Sina Finance APP